Skip to main content

Table 4 Patient preferences according to experience of BCC and treatment

From: What determines patient preferences for treating low risk basal cell carcinoma when comparing surgery vs imiquimod? A discrete choice experiment survey from the SINS trial

  

With experience

With no experience

  

Regression1

Incremental WTP (£)

Their preference is for:

Regression1

Incremental WTP (£)

Their preferences is for:

  

Value

(SD)

Value

(SD)

 

Value

(SD)

Value

(SD)

 

ASC SURGERY

Coefficient

1.6300

(0.457)

488.02

-

Surgery (comparedwith current situation)

1.3400

(0.310)

445.18

-

Surgery (compared withcurrent situation)

ASC CREAM

Coefficient

2.6100

(0.719)

781.44

-

Imiquimod cream (comparedwith current situation)

3.0500

(0.488)

1013.29

-

Imiquimod cream (compared withcurrent situation)

COST

Coefficient

−0.0033

(0.001)

  

Decreased cost

−0.0030

(0.001)

  

Decreased cost

CHANCE 2

Mean

0.0898

(0.033)

26.89

(44.61)

Increased chance (comparedwith deceased; 73% ofrespondents)

0.1210

(0.026)

40.20

(37.54)

Increased chance (compared withdecreased; 86% of respondents)

 

SD

0.1490

(0.058)

   

0.1130

(0.023)

   

MILD SIDE EFFECTS

Mean

1.1500

(0.553)

344.31

(616.77)

Mild side effects(compared with severe;71% of respondents)

1.3700

(0.390)

455.15

(541.53)

Mild side effects (compared withsevere; 80% of respondents)

 

SD

2.0600

(0.474)

   

1.6300

(0.327)

   

MODERATE SIDEEFFECTS 2–3

Mean

1.1600

(0.480)

347.31

(−153.89)

Moderate side effects(compared with severe;99% of respondents)

0.6710

(0.312)

222.92

(−199.67)

Moderate side effects (comparedwith severe; 87% of respondents)

 

SD

0.5140

(0.519)

   

0.6010

(0.423)

   

NORMALAPPEARANCE 2-3

Mean

1.3100

(0.531)

392.22

(377.25)

Normal appearance (comparedwith severe change; 97% ofrespondents)

0.9000

(0.304)

299.00

(158.80)

Normal appearance (compared withsevere change, 85% of respondents)

 

SD

1.2600

(0.633)

   

0.4780

(0.498)

   

MODERATE CHANGEIN APPEARANCE

Mean

0.9230

(0.564)

276.35

(407.19)

Moderate change(compared with severe;75% of respondents)

0.4630

(0.433)

153.82

(634.55)

Moderate change (comparedwith severe; 60% of respondents)

 

SD

1.3600

(0.539)

   

1.9100

(0.408)

   

No. respondents

 

56

118

No. observations

 

896 (=56 respondents*16 choices)

1869 (=115 respondents*16 choices+1 respondent*14 choices+1 respondent*8 choices+1 respondent*7 choices)

Log-likelihood

 

−649.27

−1350.8

Adj Rho-square

 

0.327

0.336

LR statistic

 

670.18

1405.08

  1. Note: Alternative specific constants (ASC) for surgery (ASCSURGERY) and for cream (ASCCREAM) show the preferences of these alternatives relative to the current situation, everything else being equal. WTP estimates are based on the regression results in column 3 and rounded to 2 decimal places. The standard deviations are in parentheses. 1 The preferred model is a MLM and presents all characteristics (apart from ‘COST’, ‘ASCSURGERY’, ‘ASCCREAM’) as random and independently normally distributed. The simulation process is based on 500 draws. All coefficients (either fixed or random) and the standard deviations of the random coefficients are statistically significant at 95% 2 Differences in marginal WTP between groups are significant at the 95% level. 3Differences in preference distribution between groups are significant at the 99% level.
  2. Key: SD = standard deviation, WTP = Willingness to Pay, LR = Likelihood Ratio, No. = Number of.
Back to article page

BMC Dermatology

ISSN: 1471-5945

Contact us